CN108245530A - A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes - Google Patents
A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes Download PDFInfo
- Publication number
- CN108245530A CN108245530A CN201611234792.4A CN201611234792A CN108245530A CN 108245530 A CN108245530 A CN 108245530A CN 201611234792 A CN201611234792 A CN 201611234792A CN 108245530 A CN108245530 A CN 108245530A
- Authority
- CN
- China
- Prior art keywords
- composition
- functions
- inulin
- weight
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 206010010774 Constipation Diseases 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 229920001202 Inulin Polymers 0.000 claims abstract description 39
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 39
- 229940029339 inulin Drugs 0.000 claims abstract description 39
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 37
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 37
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 239000002671 adjuvant Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 8
- 230000013872 defecation Effects 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000002550 fecal effect Effects 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000013580 sausages Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Present invention relates particularly to a kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes.The raw material of the composition forms：40~90 parts by weight of inulin, 10~60 parts by weight of beta glucan.The present invention by inulin and beta glucan by being jointly formed composition, and the two cooperates under specific proportioning, collective effect, so as to play the effect to relax bowel；The composition that inulin and beta glucan are jointly formed by being significantly better than the therapeutic effect of constipation the two individually to the therapeutic effect of constipation by the present invention；The composition that inulin and beta glucan under specific proportioning are jointly formed has the function of synergy to the therapeutic effect of constipation.
Description
Technical field
The invention belongs to drug, health products or field of food, and in particular to a kind of composition with functions of loosening bowel relieving constipation
And preparation method thereof and purposes.
Background technology
Constipation is clinical common complicated symptom, and the row's of being primarily referred to as number is reduced, excrement amount is reduced, excrement is dry and hard, defecation
It is laborious etc..When above-mentioned symptom exists simultaneously two or more, diagnosable is symptomatic constipation.Based on usually being reduced with stool interval, one
As per 2-3 days or longer time defecation once (or weekly<3 times) it is constipation.About 6.5 kilograms of place can be accumulated in enteron aisle
Just, a large amount of stool is blocked in enteron aisle so that toxin, rubbish can not be discharged or even be inhaled again as " nutrition " by enteron aisle in time
It receives, and then leads to that loss of appetite, digestive discomfort, abdomen be too fat to move, chloasma, colour table, acne etc. occurs in skin, so as to cause body
The premature aging at age, in some instances it may even be possible to induce colon cancer.Therefore, intestinal health problem increasingly attracts people's attention,
Annual May 29 is set to " world's intestinal health day " by world's gastroenterology tissue (WGO).
Chinese patent literature CN104839721A is disclosed：A kind of beverage to relax bowel, includes following weight percent
Raw material：Oligoisomaltose 6.5-7.5%, fructose syrup 7.5-8.5%, inulin 0.5-1.5%, concentrated apple clear juice 0.5-
1.0%th, polydextrose 0.2-1.0%, function additive 0.1-0.5%, additive 0-0.3%, water surplus；The drink to relax bowel
Material by the micro-ecological environment of bidirectional modulation enteron aisle and the balance of intestinal flora, promotes the breeding of probiotics in enteron aisle, inhibits rotten
The growth of bacterium is lost, is effectively improved and carries out enteron aisle health care comprehensively with bowel problems, enhancing intestinal immunities such as Constipation, diarrhea,
Strength can be avoided to drain the damage brought to body, however, there is the shortcomings of composition is complicated, cost is higher in above-mentioned composition, from
And limit its application.
Therefore, study novel therapeutic effect is good, toxic side effect is small, composition is simple, it is lower-cost have relax bowel
The composition of effect is of great significance.
Invention content
Therefore, a kind of therapeutic effect of present invention offer is good, toxic side effect is small, composition is simple, lower-cost with ease constipation
The composition of defecating feces excretion, and then preparation method and purposes are provided.
In order to solve the above technical problems, the present invention is achieved through the following technical solutions：
The present invention provides a kind of composition with functions of loosening bowel relieving constipation, and the raw material composition of the composition is：Inulin 40
~90 parts by weight, 10~60 parts by weight of beta glucan.
Preferably, the above-mentioned composition with functions of loosening bowel relieving constipation of the present invention, the raw material composition of the composition are：Inulin
50~80 parts by weight, 20~50 parts by weight of beta glucan.
It is further preferred that the above-mentioned composition with functions of loosening bowel relieving constipation of the present invention, the raw material composition of the composition
For：50 parts by weight of inulin, 50 parts by weight of beta glucan.
It is further preferred that the above-mentioned composition with functions of loosening bowel relieving constipation of the present invention, the raw material composition of the composition
For：60 parts by weight of inulin, 40 parts by weight of beta glucan.
It is further preferred that the above-mentioned composition with functions of loosening bowel relieving constipation of the present invention, the raw material composition of the composition
For：80 parts by weight of inulin, 20 parts by weight of beta glucan.
The present invention also provides a kind of preparation methods of the above-mentioned composition with functions of loosening bowel relieving constipation, include the following steps：
Take the inulin and beta glucan of selected parts by weight respectively, grind, be uniformly mixed to get.
The present invention also provides the preparation including the above-mentioned composition with functions of loosening bowel relieving constipation or including above-mentioned preparation side
The preparation for the composition that method is prepared,
The composition adds in customary adjuvant, according to common process, be made clinically acceptable tablet, capsule, dissipate
Agent, mixture, pill, granule, solution, syrup, soft extract, beverage, biscuit, candy or cake.
The customary adjuvant is：Filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, corrigent, anti-corrosion
Agent, matrix etc..Filler includes：Starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；It collapses
Solution agent includes：Starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low substitution hydroxyl
Third cellulose, cross-linked carboxymethyl cellulose are received；Lubricant includes：Magnesium stearate, lauryl sodium sulfate, talcum powder, dioxy
SiClx etc.；Suspending agent includes：Polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Bonding
Agent includes, starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；Sweetener includes：Saccharin sodium, aspartame, sugarcane
Sugar, honey element, enoxolone etc.；Corrigent includes：Sweetener and various essence；Preservative includes：Parabens, benzoic acid,
Sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc.；Matrix includes：PEG6000、
PEG4000, insect wax etc..
The present invention also provides the systems of above-mentioned composition, the composition that above-mentioned preparation method is prepared or above-mentioned composition
Application of the agent in the drug with functions of loosening bowel relieving constipation, health products or food is prepared.
Technical scheme of the present invention has the following advantages that：
(1) present invention by inulin and beta glucan by being jointly formed composition, the two phase interworking under specific proportioning
It closes, collective effect, so as to play the effect to relax bowel；
(2) present invention is by the way that the composition that inulin and beta glucan are jointly formed is significantly better than the therapeutic effect of constipation
The two is individually to the therapeutic effect of constipation；This shows inulin and the composition that is jointly formed of beta glucan under specifically matching
There is synergy to the therapeutic effect of constipation；
(3) present invention has the composition of functions of loosening bowel relieving constipation, and only including two kinds of raw materials, composition is simple, cost is relatively low.
Specific embodiment
In following embodiment and experimental example, inulin and beta glucan are commercially available product.
Embodiment 1
There is the present embodiment the raw material of the composition of functions of loosening bowel relieving constipation to form：Inulin 50g, beta glucan 50g；
The preparation method of the composition, includes the following steps：The inulin and beta glucan of selected weight are taken respectively, are ground,
Be uniformly mixed to get.
The composition that the present embodiment has functions of loosening bowel relieving constipation adds in customary adjuvant, and according to common process, tablet is made.
Embodiment 2
There is the present embodiment the raw material of the composition of functions of loosening bowel relieving constipation to form：Inulin 60g, beta glucan 40g；
The preparation method of the composition, includes the following steps：Take respectively selected weight inulin and, grind, be uniformly mixed,
To obtain the final product.
The composition that the present embodiment has functions of loosening bowel relieving constipation adds in customary adjuvant, and according to common process, capsule is made.
Embodiment 3
There is the present embodiment the raw material of the composition of functions of loosening bowel relieving constipation to form：Inulin 80g, beta glucan 20g；
The preparation method of the composition, includes the following steps：The inulin and beta glucan of selected weight are taken respectively, are ground,
Be uniformly mixed to get.
The composition that the present embodiment has functions of loosening bowel relieving constipation adds in customary adjuvant, and according to common process, powder is made.
Embodiment 4
There is the present embodiment the raw material of the composition of functions of loosening bowel relieving constipation to form：Inulin 40g, beta glucan 60g；
The preparation method of the composition, includes the following steps：The inulin and beta glucan of selected weight are taken respectively, are ground,
Be uniformly mixed to get.
The composition that the present embodiment has functions of loosening bowel relieving constipation adds in customary adjuvant, and according to common process, granule is made.
Embodiment 5
There is the present embodiment the raw material of the composition of functions of loosening bowel relieving constipation to form：Inulin 90g, beta glucan 10g；
The preparation method of the composition, includes the following steps：The inulin and beta glucan of selected weight are taken respectively, are ground,
Be uniformly mixed to get.
The composition that the present embodiment has functions of loosening bowel relieving constipation adds in customary adjuvant, and according to common process, tablet is made.
Embodiment 6
There is the present embodiment the raw material of the composition of functions of loosening bowel relieving constipation to form：Inulin 70g, beta glucan 30g；
The preparation method of the composition, includes the following steps：The inulin and beta glucan of selected weight are taken respectively, are ground,
Be uniformly mixed to get.
The composition that the present embodiment has functions of loosening bowel relieving constipation adds in customary adjuvant, and according to common process, capsule is made.
Comparative example 1
This comparative example has the composition of functions of loosening bowel relieving constipation and differing only in for embodiment 1：Raw material forms：Inulin
10g, beta glucan 90g；
The preparation method of the composition is differed only in embodiment 1：Raw material forms：Inulin 10g, beta glucan
90g；Remaining experiment condition and laboratory operating procedures are same as Example 1.
Comparative example 2
This comparative example has the composition of functions of loosening bowel relieving constipation and differing only in for embodiment 1：Raw material forms：Inulin
50g, beta glucan 0g；
The preparation method of the composition is differed only in embodiment 1：Raw material forms：Inulin 50g, beta glucan
0g；Remaining experiment condition and laboratory operating procedures are same as Example 1.
Comparative example 3
This comparative example has the composition of functions of loosening bowel relieving constipation and differing only in for embodiment 1：Raw material forms：Inulin
0g, beta glucan 50g；
The preparation method of the composition is differed only in embodiment 1：Raw material forms：Inulin 0g, beta glucan
50g；Remaining experiment condition and laboratory operating procedures are same as Example 1.
Experimental example 1The research of present composition functions of loosening bowel relieving constipation
1st, experimental method
In order to show effect that the present composition relaxes bowel, 250 constipation patients is selected to carry out system clinical observations.
3 groups for the treatment of group, blank control group, 1 group of control group, 2 groups of control group and control group are randomly assigned each 50, are treated using treatment group
Two kinds of forms are compareed between cross-reference and group, record its medical history, the state of an illness and therapeutic effect.
Treatment group：Composition prepared by embodiment 1,1 time a day, each 15g, continuous 30 days.
Blank control group：Placebo, 1 time a day, each 15g, continuous 30 days；
1 group of control group：Composition prepared by comparative example 1,1 time a day, each 15g, continuous 30 days；
2 groups of control group：Composition prepared by comparative example 2,1 time a day, each 15g, continuous 30 days；
3 groups of control group：Composition prepared by comparative example 3,1 time a day, each 15g, continuous 30 days.
During the experiment requirement each group does not change original eating habit, normal diet.
2nd, the evaluation principle of therapeutic effect
The evaluation of the therapeutic effect of each group is evaluated according to following principle in this experiment,
1) daily defecation frequency：The variation of defecation frequency before and after record subject's test-meal.
2) defecation condition：According to difficult defecation degree (abdominal pain or anus burn feeling, bearing down, sense of discomfort, whether just frequency but
Difficult defecation and the symptoms such as a small amount of) it is divided into I~IV grade, count integrated value.
I grades (0 points)：Defecation is normal；
II grade (1 point)：Only bearing down, sense of discomfort；
III grade (2 points)：Bearing down, sense of discomfort are apparent or have just frequency but difficult defecation and measure less, less abdominal pain or anus occur
Door burn feeling；
IV grade (3 points)：Often there is abdominal pain or anus burn feeling, influence defecation.
3) fecal character：Fecal character is divided by I~III grade according to Bristol (Bristol) fecal character classification.
I grades (0 points)：It is smooth and soft as sausage or snake；As sausage, but there is slight crack on its surface；Soft agglomerate, has
Apparent edge (being easily drained)；
II grade (1 point)：Sausage shape, but have agglomerate；Loose bulk, edge roughness, as slimy excrement；
III grade (2 points)：The hard group of separation, as fruit stone (being not easy to discharge).
Pretherapy and post-treatment each group patient itself, which compares defecation frequency, significantly to be increased, in defecation condition and fecal character binomial index
One index integration is decreased obviously, and difference is statistically significant；Treatment group and blank control group after treatment, compare 1 group of control group
3 groups of 2 groups of group and control group compare, and any one of defecation frequency, defecation condition and fecal character are obviously improved, and difference has statistics meaning
Justice.Can be shown that above has therapeutic effect to constipation.
3rd, experimental result
The results are shown in Table 1 for specific experiment.
The specific experiment result of 1 each group of table
| Group | Number of cases | Effective number of cases | Effective number of cases | Invalid number of cases | Total effective rate (%) |
| Blank control group | 50 | 8 | 4 | 38 | 24 |
| 1 group of control group | 50 | 14 | 7 | 27 | 42 |
| 2 groups of control group | 50 | 10 | 5 | 34 | 30 |
| 3 groups of control group | 50 | 11 | 2 | 37 | 26 |
| Treatment group | 50 | 27 | 20 | 3 | 94.3 |
As shown in Table 1, (1) compared with pre-treatment, after composition prepared by treatment group's embodiment 1 treatment, defecation frequency
It dramatically increases, defecation condition average integral is remarkably decreased, and fecal character average integral is remarkably decreased；This shows prepared by embodiment 1
Composition to constipation have significant therapeutic effect；
(2) after treating, compared with 3 groups of blank control group, 1 group of control group, 2 groups of control group and control group, treatment group controls
It treats total effective rate to significantly improve, difference is statistically significant；This shows compared with composition prepared by comparative example 1,2,3, implements
Composition prepared by example 1 is more notable to the therapeutic effect of constipation；Composition prepared by embodiment 1 has the therapeutic effect of constipation
Synergistic effect.
4th, experiment conclusion
In conclusion the present composition has the function of to relax bowel, there is significant therapeutic effect to constipation, it can be with
As drug, health products or the food for preventing or treating constipation.
Obviously, the above embodiments are merely examples for clarifying the description, and is not intended to limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And the obvious variation thus extended out or
Among changing still in the protection domain of the invention.
Claims (8)
1. a kind of composition with functions of loosening bowel relieving constipation, which is characterized in that the raw material of the composition, which forms, is：Inulin 40~
90 parts by weight, 10~60 parts by weight of beta glucan.
2. the composition according to claim 1 with functions of loosening bowel relieving constipation, which is characterized in that the raw material of the composition
It forms and is：50~80 parts by weight of inulin, 20~50 parts by weight of beta glucan.
3. the composition according to claim 2 with functions of loosening bowel relieving constipation, which is characterized in that the raw material of the composition
It forms and is：50 parts by weight of inulin, 50 parts by weight of beta glucan.
4. the composition according to claim 2 with functions of loosening bowel relieving constipation, which is characterized in that the raw material of the composition
It forms and is：60 parts by weight of inulin, 40 parts by weight of beta glucan.
5. the composition according to claim 2 with functions of loosening bowel relieving constipation, which is characterized in that the raw material of the composition
It forms and is：80 parts by weight of inulin, 20 parts by weight of beta glucan.
6. a kind of claim 1-5 any one of them has the preparation method of the composition of functions of loosening bowel relieving constipation, feature exists
In including the following steps：
Take the inulin and beta glucan of selected parts by weight respectively, grind, be uniformly mixed to get.
7. having the preparation of the composition of functions of loosening bowel relieving constipation including claim 1-5 any one of them or including right
It is required that the preparation for the composition that the preparation method described in 6 is prepared, which is characterized in that
The composition adds in customary adjuvant, and according to common process, clinically acceptable tablet, capsule, powder, conjunction is made
Agent, pill, granule, solution, syrup, soft extract, beverage, biscuit, candy or cake.
8. the composition that the preparation method described in claim 1-5 any one of them composition, claim 6 is prepared,
Or the preparation of the composition described in claim 7 answering in the drug with functions of loosening bowel relieving constipation, health products or food is prepared
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611234792.4A CN108245530A (en) | 2016-12-28 | 2016-12-28 | A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611234792.4A CN108245530A (en) | 2016-12-28 | 2016-12-28 | A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108245530A true CN108245530A (en) | 2018-07-06 |
Family
ID=62719904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611234792.4A Pending CN108245530A (en) | 2016-12-28 | 2016-12-28 | A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108245530A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604245A (en) * | 2019-09-27 | 2019-12-24 | 济南泰和医药科技有限公司 | Oral solid beverage for coordinating intestines and stomach and regulating blood sugar |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060123A1 (en) * | 2009-11-12 | 2011-05-19 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
| CN102805351A (en) * | 2012-08-21 | 2012-12-05 | 运城学院 | Continuous preparation method of black wheat dietary fiber |
| CN104448028A (en) * | 2014-11-27 | 2015-03-25 | 广东省食品工业研究所 | Method for recycling ethyl alcohol in oat beta-glucan and obtaining dried and sterile oat beta-glucan by gradually warming rising temperature |
| CN105707895A (en) * | 2016-01-25 | 2016-06-29 | 朱喜艳 | Hulless barley enzyme beta-glucan and hulless barley enzyme beta-glucan propagation method |
| CN106173572A (en) * | 2015-04-30 | 2016-12-07 | 北京斯利安药业有限公司 | A kind of maternal nutritional fortified compositions and preparation method thereof |
-
2016
- 2016-12-28 CN CN201611234792.4A patent/CN108245530A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060123A1 (en) * | 2009-11-12 | 2011-05-19 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
| CN102805351A (en) * | 2012-08-21 | 2012-12-05 | 运城学院 | Continuous preparation method of black wheat dietary fiber |
| CN104448028A (en) * | 2014-11-27 | 2015-03-25 | 广东省食品工业研究所 | Method for recycling ethyl alcohol in oat beta-glucan and obtaining dried and sterile oat beta-glucan by gradually warming rising temperature |
| CN106173572A (en) * | 2015-04-30 | 2016-12-07 | 北京斯利安药业有限公司 | A kind of maternal nutritional fortified compositions and preparation method thereof |
| CN105707895A (en) * | 2016-01-25 | 2016-06-29 | 朱喜艳 | Hulless barley enzyme beta-glucan and hulless barley enzyme beta-glucan propagation method |
Non-Patent Citations (1)
| Title |
|---|
| 张平等: "菊粉水溶性膳食纤维对便秘的作用", 《食品安全导刊》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604245A (en) * | 2019-09-27 | 2019-12-24 | 济南泰和医药科技有限公司 | Oral solid beverage for coordinating intestines and stomach and regulating blood sugar |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN116549494B (en) * | 2023-07-07 | 2023-09-01 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2473209C (en) | Stimulation of the immune system with polydextrose | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| CN102258735B (en) | Medicine for treating fore-stomach stony and impaction of rumen in cows and preparation method thereof | |
| CN104524110A (en) | Traditional Chinese medicine composition with functions of tonifying spleen and clearing damp | |
| CN112544920A (en) | Composition for improving constipation and preparation method thereof | |
| CN106901153A (en) | Sub- Ke Fen ∕ wheat bran composite powders and preparation method thereof before circle bud car | |
| CN111480851A (en) | Intestinal tract exclusive active polypeptide composition for improving human body circulation | |
| EP1980258A1 (en) | Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same | |
| CN104107188A (en) | Application and preparation method of apple polysaccharides for regulating alteration of intestinal flora and relaxing bowel | |
| JPH05255097A (en) | Liquid composition | |
| CN108245530A (en) | A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes | |
| CN109645501A (en) | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence | |
| Tabrizi et al. | Functional laxative foods: Concepts, trends and health benefits | |
| JP4113242B1 (en) | Gastrointestinal symptoms | |
| CN101450074B (en) | Composition capable of greatly improving gastrointestinal tract function and preventing and treating astriction | |
| JP2005179316A (en) | Composition with constipation ameliorating action | |
| CN108245531A (en) | It is a kind of to improve gastrointestinal function, the anti-composition to treat constipation | |
| JP7219907B2 (en) | Composition for improving lower urinary tract symptoms | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| CN108245604A (en) | A kind of composition of relief of constipation and preparation method thereof and purposes | |
| JPH09278664A (en) | New dietary fiber composition | |
| CN105685983A (en) | Health-care food with defaecation function and preparation method of health-care food | |
| WO2008096171A2 (en) | Natural laxative composition comprising prunes, raisins, apricots, dates, figs, olive oil, senna and honey | |
| JP6795662B2 (en) | Uroplakin expression promoter | |
| JP4071818B1 (en) | sweetener |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180706 |
|
| RJ01 | Rejection of invention patent application after publication |